Phase 3 is where the peptide pipeline actually monetizes. The trials that drive prescribing labels and payer coverage land here.
Recent and active Phase 3 programs covered on this site: SURMOUNT-5 (tirzepatide vs semaglutide), ACHIEVE-3 (orforglipron in obesity), TRIUMPH (retatrutide), REDEFINE-1 and -2 (CagriSema), SYNCHRONIZE-1 (Zealand's survodutide), REMODEL (semaglutide kidney), the SELECT cardiovascular outcomes trial, BriaCell's Bria-IMT in metastatic breast cancer, and AMPLIFY-201 (ELI-002 KRAS vaccine). Outside obesity and oncology, Boehringer Ingelheim, Crinetics, Verismo, and Lirum have active Phase 3 readouts in adjacent indications.
Stories here cover top-line readouts, full-data presentations at AACR, AAN, ESCMID, and AOSSM, and the FDA filings that follow.
Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced Wednesday August 19, 2026 that the Phase 3 INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157, an individualized neoantigen therapy) plus pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in adults with high-risk (Stage IIB-IV) resected cutaneous melanoma compared to Keytruda alone. Mechanism: intismeran autogene is a personalized mRNA therapy that encodes up to 34 tumor-specific neoantigen peptides selected from the individual patient's tumor mutation signature. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The Phase 3 readout is the first positive Phase 3 for an individualized neoantigen therapy and the first Phase 3 to demonstrate substantial improvement over Keytruda alone in the adjuvant melanoma setting. Trial design: randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 evaluating safety and efficacy of the combination versus Keytruda alone. Phase 2b KEYNOTE-942 five-year follow-up data presented at the 2026 ASCO Annual Meeting had shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death for the combination versus Keytruda alone, and the Phase 3 readout confirms and extends those benefits. The result validates the personalized neoantigen mRNA vaccine platform and opens a substantial commercial pathway for the Merck-Moderna collaboration in adjuvant oncology settings beyond melanoma including non-small-cell lung cancer, renal cell carcinoma, and cutaneous squamous cell carcinoma where INTerpath studies are ongoing.
The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.
Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.7% mean weight loss at 68 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.
Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026. Trial status: the last participant completed the final study visit in the 16-week double-blind period. Trial design: 78 patients with post-bariatric hypoglycemia (PBH) enrolled across 21 US sites and randomized 3:2 to avexitide 90 mg subcutaneous once daily or placebo for 16 weeks. Primary endpoint (agreed with the FDA): reduction in the composite of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events through Week 16. The trial design was informed by data from five prior clinical trials of avexitide in post-bariatric hypoglycemia that consistently showed statistically significant reductions in Level 2 and Level 3 hypoglycemic events. Avexitide is exendin (9-39), a peptide GLP-1 receptor antagonist that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in patients following Roux-en-Y gastric bypass surgery. If positive, commercial launch of avexitide is anticipated in 2027 for the indication that has no currently approved drug therapy. LUCIDITY is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism.
Amylyx Pharmaceuticals (NASDAQ: AMLX) confirmed on the August 6, 2026 Q2 2026 earnings call that top-line data from the registrational Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia will read out in late August or early September 2026. Avexitide (formerly XOMA 358) is exendin (9-39), a peptide GLP-1 receptor antagonist: a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking endogenous GLP-1 signaling. This is the mechanistic opposite of semaglutide, tirzepatide, and the other GLP-1 receptor agonists. Post-bariatric hypoglycemia (PBH) is a serious complication of Roux-en-Y gastric bypass surgery affecting roughly 8% of patients long-term and manifesting as postprandial hypoglycemia (dangerously low blood sugar after meals) driven by excessive GLP-1 signaling in the reconfigured GI anatomy. Avexitide blocks GLP-1 receptor activation to normalize postprandial glucose. Q2 2026 EPS of -$0.39 missed the -$0.35 consensus by $0.04 (11% below forecast). The LUCIDITY readout is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism. If positive, avexitide would represent a first-in-class approved therapy for post-bariatric hypoglycemia, an indication with no currently approved drug therapy.
Novo Nordisk released detailed data from the REDEFINE 4 head-to-head 84-week Phase 3 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg. Trial design: 809 randomized adults with obesity and one or more comorbidities with mean baseline body weight of 114.2 kg, both drugs administered once weekly subcutaneously over 84 weeks. Primary endpoint results: CagriSema 23.0% weight loss versus tirzepatide 25.5% (treatment-policy estimand); CagriSema 20.2% versus tirzepatide 23.6% (treatment-regimen estimand). The trial missed the primary non-inferiority endpoint on weight loss for CagriSema compared to tirzepatide at 84 weeks. CagriSema safety profile was generally well-tolerated. The trial result complicates the Novo commercial positioning of CagriSema as its tirzepatide-beating differentiated response, though the FDA decision on the CagriSema obesity indication remains expected late 2026 based on the REDEFINE 1 and REDEFINE 2 pivotal trials submitted December 18, 2025. The head-to-head result adds to the widening Lilly-Novo franchise gap: Lilly Q2 2026 Mounjaro + Zepbound reached $14.9 billion in the quarter, while Novo H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion).
Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) reportedly failed to control blood sugar as effectively as Eli Lilly's tirzepatide (Mounjaro/Zepbound) in a head-to-head Phase 3 trial of patients with type 2 diabetes. CagriSema regulatory filing was submitted December 18, 2025 with an expected FDA decision in late 2026 for obesity indication; the type 2 diabetes head-to-head failure complicates the commercial narrative and label-expansion strategy. The trial outcome adds to the widening Lilly-Novo franchise gap documented across the Q2 2026 earnings week: Eli Lilly (NYSE: LLY) Q2 revenue reached $23 billion (+48% year-over-year) with Foundayo (orforglipron oral small-molecule GLP-1) delivering $98 million in its first fully operational commercial quarter and Mounjaro + Zepbound combined at $14.9 billion; Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency) with shares declining 5% on margin-compression concerns despite raised guidance. Investor narrative on Novo's ability to defend GLP-1 franchise economics continues to deteriorate as the amylin analog (cagrilintide) that Novo positioned as its differentiator against tirzepatide's dual GIP/GLP-1 mechanism failed to close the efficacy gap in the head-to-head setting.
Amgen (NASDAQ: AMGN) reported Q2 2026 earnings Tuesday August 4, 2026 with a beat and raised full-year 2026 revenue guidance to $38.2-39.4 billion (midpoint $38.8 billion above the $37.7 billion analyst consensus). Adjusted EPS guidance is $22.30-23.50 (midpoint $22.90 above the $22.35 consensus). Growth-portfolio product performance drove the beat: Repatha (evolocumab, PCSK9 monoclonal antibody) reached $953 million (+37% year-over-year); EVENITY (romosozumab for osteoporosis) $714 million (+38%); TEZSPIRE (tezepelumab for severe asthma) $486 million (+42%); UPLIZNA (inebilizumab for neuromyelitis optica spectrum disorder) $335 million (+90%). The MariTide (maridebart cafraglutide, monthly-injectable antibody-peptide conjugate targeting GLP-1 and GIPR) Phase 3 obesity program continues advancing with multiple trials across weight management, cardiovascular outcomes, and heart failure indications; earnings-call commentary described 2026 as a year of disciplined MariTide data generation. Analyst scrutiny remains on the 4% bone mineral density decline observed in Phase 1 MariTide data (per Cantor Fitzgerald analysis) as a potential regulatory hurdle and safety disadvantage versus GLP-1 receptor agonist competitors. Amgen shares closed up 3.03% on August 4.
Boehringer Ingelheim's survodutide (BI 456906) Phase 2 MASH results continue to circulate through the pharma analyst community ahead of Phase 3 readouts expected in late 2026. Survodutide is a dual GLP-1 / glucagon receptor agonist administered by once-weekly subcutaneous injection. In the Phase 2 trial in patients with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH), 83% of survodutide-treated patients achieved histological improvement at 48 weeks (versus placebo comparator). Phase 3 trials for both MASH (LIVERAGE program) and obesity (SYNCHRONIZE program) are underway. Survodutide positions Boehringer Ingelheim to compete against Novo Nordisk semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) which has approximately 15% weight loss and Rezdiffra (resmetirion) FDA-approved March 2024 for MASH; Eli Lilly tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) which has approximately 21% weight loss; and the eventual Eli Lilly retatrutide triple GLP-1/GIP/glucagon agonist (Phase 3 TRIUMPH program) which showed 28.3% weight loss in Phase 3 obesity readouts earlier in 2026. The dual-agonist glucagon mechanism differentiates survodutide from the pure GLP-1 and GLP-1/GIP incumbents by adding hepatic glucose output modulation and potential MASH-specific liver benefit.
Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) presented detailed Phase 3 ISLEND-1 and ISLEND-2 Week 48 data during the late-breaking session at AIDS 2026 Wednesday July 29, 2026 in Rio de Janeiro. The investigational once-weekly oral single-tablet regimen of islatravir 2 mg / lenacapavir 300 mg (ISL/LEN) demonstrated non-inferior efficacy versus daily standard-of-care antiretroviral therapy in virologically-suppressed adults living with HIV who switched from daily Biktarvy (ISLEND-1) or other daily oral regimens (ISLEND-2). Primary endpoint results: 0% of ISLEND-1 participants on once-weekly ISL/LEN had HIV-1 RNA at 50 copies/mL or higher at Week 48 compared to 0.3% remaining on daily Biktarvy; in the open-label ISLEND-2 trial, 0.3% of participants on ISL/LEN had HIV-1 RNA at 50 copies/mL or higher versus 1.3% on daily standard-of-care regimens. Safety profile was generally similar to comparator regimens with no new safety signals identified. The Week 48 data will support planned regulatory submissions for the first once-weekly oral HIV treatment regimen. Lenacapavir is Gilead's first-in-class HIV capsid inhibitor; islatravir is Merck's nucleoside reverse transcriptase translocation inhibitor (NRTTI).
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.
The 26th International AIDS Conference (AIDS 2026) opens Sunday July 26, 2026 in Rio de Janeiro, Brazil and runs through July 31. Gilead Sciences and Merck's Phase 3 ISLEND-1 and ISLEND-2 detailed data on the investigational once-weekly oral HIV treatment regimen islatravir 2 mg / lenacapavir 300 mg (ISL/LEN) is scheduled for the late-breaking session on Wednesday July 29. Topline numbers released July 21 showed 0% of once-weekly ISL/LEN participants had HIV-1 RNA at 50 copies/mL or higher at Week 48 in ISLEND-1 (versus 0.3% of participants who remained on daily Biktarvy). In ISLEND-2, 0.3% of participants receiving weekly ISL/LEN had HIV-1 RNA at 50 copies/mL or higher versus 1.3% on daily standard of care regimens. Safety profile was generally similar to comparator regimens with no new signals identified. Lenacapavir is a first-in-class HIV capsid inhibitor (peptide-adjacent modality); islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). The data will support planned regulatory submissions and represents the first once-weekly oral HIV treatment regimen to clear Phase 3 endpoints. Merck also plans to present daily, weekly, and monthly HIV treatment and prevention pipeline updates at AIDS 2026.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported positive Phase 3 topline results Thursday July 23, 2026 from the SHASTA-3 and SHASTA-4 studies of plozasiran, an ApoC-III-targeting siRNA administered as a 25 mg subcutaneous injection once every three months, in adults with severe hypertriglyceridemia (sHTG). Both trials met their primary endpoint: median triglyceride reductions of 79% (SHASTA-3) and 81% (SHASTA-4) at Month 12 versus approximately 27% for placebo. All prespecified secondary endpoints were met, including a statistically significant reduction in the rate of acute pancreatitis events compared with placebo. Arrowhead shares rose approximately 19% on the readout. The company plans to file a supplemental New Drug Application (sNDA) with the US FDA before the end of 2026 for the sHTG indication (which extends the current Redemplo label from familial chylomicronemia syndrome), and Arrowhead intends to use the SHASTA-3, SHASTA-4, and MUIR-3 program data for marketing authorization filings across multiple global geographies. Plozasiran is a nucleic-acid therapeutic (siRNA), an adjacent-modality to peptides that operates through RNA interference at the ApoC-III gene expression level to lower circulating triglycerides.
Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.
Biogen (NASDAQ: BIIB) presented full Phase 2 CELIA study data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide (ASO) delivered intrathecally, at AAIC 2026 in London on Tuesday July 14, 2026 during the Developing Topics in Phase 2 Clinical Trials Session (2:00-3:30 PM BST). The 76-week placebo-controlled study evaluated three doses (60 mg every 24 weeks, 115 mg every 24 weeks, and 115 mg every 12 weeks) and did not meet its primary endpoint of dose response on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 76. Strong reductions in tau pathology occurred across all studied doses, generally consistent with the Phase 1b study. Prespecified analyses of cognitive endpoints demonstrated slowing of clinical decline across all doses, with the effect particularly pronounced at the lowest 60 mg q24w dose. Biogen framed the results as the first randomized Phase 2 evidence of a tau-directed therapy showing both biomarker impact and cognitive benefit, and plans to advance diranersen to registrational Phase 3 development.
MindRank AI, a Chinese clinical-stage biotech built around a proprietary Molecule Arts Platform (MAP) integrating biology, chemistry, computation, experimental evidence, and clinical learning, announced Thursday July 9, 2026 the completion of a $52 million Series B financing led by a group of institutional and healthcare funds. The company's lead program, MDR-001, is an AI-designed oral small-molecule GLP-1 receptor agonist that entered Phase 3 development in China in 2025 with the initiation of the MOBILE Phase 3 trial enrolling approximately 750 participants with overweight or obesity. The trial evaluates 52-week efficacy and safety. MindRank reports cumulative R&D investment from project initiation through the start of Phase 3 in China of approximately $23 million, with the program advancing from concept to Phase 3 in roughly 4.5 years. The financing extends the oral-GLP-1 competitive set beyond Eli Lilly's Foundayo (orforglipron), Novo Nordisk's Wegovy pill (oral semaglutide 25 mg), and Structure Therapeutics' aleniglipron. Anticipated commercial launch: within two to three years.
Rhythm Pharmaceuticals announced Wednesday July 8, 2026 that Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE), a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in the New England Journal of Medicine. TRANSCEND is the largest and longest placebo-controlled clinical trial ever conducted in acquired hypothalamic obesity, a rare and severe metabolic condition caused by damage to the hypothalamus from tumors, surgery, radiation, or trauma. The publication documents weight and hunger improvements in adult and pediatric patients aged four years and older across the treatment arm versus placebo control. IMCIVREE is already FDA-approved as a once-daily subcutaneous injection for chronic weight management in adults and pediatric patients aged four and older with acquired hypothalamic obesity, as well as for syndromic or monogenic obesity in patients with confirmed loss-of-function variants. The NEJM publication follows the earlier Kalohexis confidential IPO filing (July 7-8) on the dual MC3R/MC4R melanocortin platform, sustaining momentum around melanocortin biology as the highest-profile non-GLP-1 obesity mechanism in commercial development.
On July 7, Kailera Therapeutics reported positive topline results from two Hengrui Pharma Phase 3 trials in China of HRS-7535/KAI-7535, a once-daily oral small-molecule GLP-1 receptor agonist licensed to Kailera outside Greater China. In HARBOR-1, 556 adults with obesity or overweight lost a mean 9.5% of body weight at 120 mg and 10.9% at 180 mg by week 44. OUTSTAND-2, in 810 adults with type 2 diabetes, showed HbA1c reductions of 1.50% to 1.68% and non-inferiority versus dapagliflozin. Hengrui plans China NDA filings; Kailera is running a parallel global Phase 2.